Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.

MLA

Lennerz, Volker, et al. “Immunologic Response to the Survivin-Derived Multi-Epitope Vaccine EMD640744 in Patients with Advanced Solid Tumors.” Cancer Immunology, Immunotherapy : CII, vol. 63, no. 4, Apr. 2014, pp. 381–94. EBSCOhost, https://doi.org/10.1007/s00262-013-1516-5.

APA

Lennerz, V., Gross, S., Gallerani, E., Sessa, C., Mach, N., Boehm, S., Hess, D., von Boehmer, L., Knuth, A., Ochsenbein, A. F., Gnad-Vogt, U., Zieschang, J., Forssmann, U., Woelfel, T., & Kaempgen, E. (2014). Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology, Immunotherapy : CII, 63(4), 381–394. https://doi.org/10.1007/s00262-013-1516-5

Chicago

Lennerz, Volker, Stefanie Gross, Elisa Gallerani, Cristiana Sessa, Nicolas Mach, Steffen Boehm, Dagmar Hess, et al. 2014. “Immunologic Response to the Survivin-Derived Multi-Epitope Vaccine EMD640744 in Patients with Advanced Solid Tumors.” Cancer Immunology, Immunotherapy : CII 63 (4): 381–94. doi:10.1007/s00262-013-1516-5.